The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 22, 2014
Filed:
Feb. 12, 2010
Triazole and imidazole derivatives for use as tgr5 agonists in the treatment of diabetes and obesity
Venkataiah Bollu, San Diego, CA (US);
Brant Clayton Boren, San Diego, CA (US);
Jackaline Dalgard Julien, Del Mar, CA (US);
Brenton T. Flatt, Poway, CA (US);
Nadia Haq, Waltham, MA (US);
Sarah Hudson, San Diego, CA (US);
Raju Mohan, Encinitas, CA (US);
Michael Morrissey, Danville, CA (US);
Benjamin Pratt, Encinitas, CA (US);
Tie-lin Wang, San Diego, CA (US);
Richard Martin, San Diego, CA (US);
Xiao-hui Gu, Potomac, MD (US);
Venkataiah Bollu, San Diego, CA (US);
Brant Clayton Boren, San Diego, CA (US);
Jackaline Dalgard Julien, Del Mar, CA (US);
Brenton T. Flatt, Poway, CA (US);
Nadia Haq, Waltham, MA (US);
Sarah Hudson, San Diego, CA (US);
Raju Mohan, Encinitas, CA (US);
Michael Morrissey, Danville, CA (US);
Benjamin Pratt, Encinitas, CA (US);
Tie-Lin Wang, San Diego, CA (US);
Richard Martin, San Diego, CA (US);
Xiao-Hui Gu, Potomac, MD (US);
Exelixis Patent Company LLC, South San Francisco, CA (US);
Abstract
The present invention comprises TGR5 agonists of structural formula I, wherein X, R, R, and Rare defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which TGR5 is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which TGR5 is a mediator or is implicated.